CBD Gel for Bruxism: Why Similar Results Do Not Prove Equal Strengths
A small controlled trial reported improvements with both 5% and 10% CBD gels, without a significant difference between strengths. That is not a formal demonstration that the two strengths are therapeutically equivalent.
The intervention and outcomes
Sixty participants with bruxism-associated muscular pain were assigned equally to placebo, 5% CBD gel or 10% CBD gel. The gels were applied intraorally over a 30-day period. Outcomes included sleep-quality and migraine-disability questionnaires, with muscle-activity assessments also reported.
This was a specific localized formulation in a selected clinical population. Its results should not be generalized to all CBD creams, ordinary swallowed CBD or every cause of migraine and poor sleep.
A positive comparison and a null comparison
The CBD groups showed significant questionnaire improvements compared with control. The comparison between CBD strengths was not significant. Those statements answer different questions: whether each treatment differed from placebo, and whether the study detected a difference between the active treatments.
Equivalence requires a justified margin and an analysis capable of excluding clinically important differences. Failure to detect a difference is insufficient, especially in a small sample.
Sample-size and mechanism limitations
The methods acknowledge a recalculation indicating approximately 26 participants per group would have been needed under the stated planning assumptions, compared with 20 actually studied. A post hoc power calculation does not erase uncertainty in the active-strength comparison.
Associations between reduced muscle activity and improved questionnaires do not establish the entire mechanism. The trial also did not establish long-term benefit, a systemic CBD concentration or a driving-impairment outcome. Its findings support further investigation of the particular intervention, with the strength of each inference matched to the design.
Related analysis
See our analysis of why a cannabinoid formulation is part of the exposure.
Primary research
Karolina Walczyńska-Dragon and colleagues. Expanding the Therapeutic Profile of Topical Cannabidiol in Temporomandibular Disorders: Effects on Sleep Quality and Migraine Disability in Patients with Bruxism-Associated Muscle Pain. Pharmaceuticals, 2025. DOI: 10.3390/ph18071064.



